Unknown

Dataset Information

0

Structures of human constitutive nitric oxide synthases.


ABSTRACT: Mammals produce three isoforms of nitric oxide synthase (NOS): neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS). The overproduction of NO by nNOS is associated with a number of neurodegenerative disorders; therefore, a desirable therapeutic goal is the design of drugs that target nNOS but not the other isoforms. Crystallography, coupled with computational approaches and medicinal chemistry, has played a critical role in developing highly selective nNOS inhibitors that exhibit exceptional neuroprotective properties. For historic reasons, crystallography has focused on rat nNOS and bovine eNOS because these were available in high quality; thus, their structures have been used in structure-activity-relationship studies. Although these constitutive NOSs share more than 90% sequence identity across mammalian species for each NOS isoform, inhibitor-binding studies revealed that subtle differences near the heme active site in the same NOS isoform across species still impact enzyme-inhibitor interactions. Therefore, structures of the human constitutive NOSs are indispensible. Here, the first structure of human neuronal NOS at 2.03?Å resolution is reported and a different crystal form of human endothelial NOS is reported at 1.73?Å resolution.

SUBMITTER: Li H 

PROVIDER: S-EPMC4188008 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structures of human constitutive nitric oxide synthases.

Li Huiying H   Jamal Joumana J   Plaza Carla C   Pineda Stephanie Hai SH   Chreifi Georges G   Jing Qing Q   Cinelli Maris A MA   Silverman Richard B RB   Poulos Thomas L TL  

Acta crystallographica. Section D, Biological crystallography 20140927 Pt 10


Mammals produce three isoforms of nitric oxide synthase (NOS): neuronal NOS (nNOS), inducible NOS (iNOS) and endothelial NOS (eNOS). The overproduction of NO by nNOS is associated with a number of neurodegenerative disorders; therefore, a desirable therapeutic goal is the design of drugs that target nNOS but not the other isoforms. Crystallography, coupled with computational approaches and medicinal chemistry, has played a critical role in developing highly selective nNOS inhibitors that exhibit  ...[more]

Similar Datasets

| S-EPMC3103786 | biostudies-literature
| S-EPMC2677215 | biostudies-literature
| S-EPMC2519002 | biostudies-literature
| S-EPMC3411954 | biostudies-literature
2017-11-03 | GSE92263 | GEO
| S-EPMC4156747 | biostudies-literature
| S-EPMC1221991 | biostudies-other
| S-EPMC1698664 | biostudies-literature
| S-EPMC2442334 | biostudies-literature
| S-EPMC3406312 | biostudies-literature